Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 4 years, with Sep 2025 value amounting to $101.3 million.

  • Agios Pharmaceuticals' Total Non-Current Liabilities fell 38.23% to $101.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.3 million, marking a year-over-year decrease of 38.23%. This contributed to the annual value of $121.4 million for FY2024, which is 2.87% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Total Non-Current Liabilities stood at $101.3 million, which was down 0.29% from $101.6 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $164.0 million in Q3 2024 and a low of $88.1 million during Q1 2025.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $113.5 million (2023), whereas its average is $115.4 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 37.49% in 2024, then crashed by 38.23% in 2025.
  • Over the past 4 years, Agios Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $134.6 million in 2022, then dropped by 7.19% to $124.9 million in 2023, then decreased by 2.87% to $121.4 million in 2024, then crashed by 38.23% to $101.3 million in 2025.
  • Its Total Non-Current Liabilities was $101.3 million in Q3 2025, compared to $101.6 million in Q2 2025 and $88.1 million in Q1 2025.